FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136231489> ?p ?o ?g. }

• W3136231489 endingPage "5764" @default.
• W3136231489 startingPage "5753" @default.
• W3136231489 abstract "The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechallenge.We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analysed in both groups. The modalities and outcomes of ICI rechallenge were reviewed.Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n = 14/16) and all had a complete response within ≤3 weeks. The efficacy of oral steroids for non-severe typical irM (n = 10) was the same with low-dose (≤0.5 mg/kg/day) or high-dose (1 mg/kg/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n = 4) had a less favourable evolution, including one irM-related death, and required heavy immunosuppression. ICIs were safely reintroduced in nine patients presenting a moderate (n = 6) or a severe (n = 3) irM.Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favour of a safe reintroduction of ICI following symptom resolution and creatin kinase (CK) normalization in moderate and severe forms of irM." @default.
• W3136231489 created "2021-03-29" @default.
• W3136231489 creator A5000662815 @default.
• W3136231489 creator A5001586790 @default.
• W3136231489 creator A5005673493 @default.
• W3136231489 creator A5010050124 @default.
• W3136231489 creator A5011037498 @default.
• W3136231489 creator A5012112773 @default.
• W3136231489 creator A5015039672 @default.
• W3136231489 creator A5025478490 @default.
• W3136231489 creator A5035640410 @default.
• W3136231489 creator A5037838523 @default.
• W3136231489 creator A5041302754 @default.
• W3136231489 creator A5042125003 @default.
• W3136231489 creator A5042939436 @default.
• W3136231489 creator A5044024585 @default.
• W3136231489 creator A5044284945 @default.
• W3136231489 creator A5045707486 @default.
• W3136231489 creator A5048569749 @default.
• W3136231489 creator A5050382913 @default.
• W3136231489 creator A5052059190 @default.
• W3136231489 creator A5056239572 @default.
• W3136231489 creator A5056853165 @default.
• W3136231489 creator A5058100097 @default.
• W3136231489 creator A5063103135 @default.
• W3136231489 creator A5067323699 @default.
• W3136231489 creator A5069462815 @default.
• W3136231489 creator A5077749760 @default.
• W3136231489 creator A5079437832 @default.
• W3136231489 creator A5081385384 @default.
• W3136231489 creator A5089551729 @default.
• W3136231489 date "2021-03-16" @default.
• W3136231489 modified "2023-10-18" @default.
• W3136231489 title "Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study" @default.
• W3136231489 cites W2096322385 @default.
• W3136231489 cites W2166662937 @default.
• W3136231489 cites W2549772877 @default.
• W3136231489 cites W2565782504 @default.
• W3136231489 cites W2760893760 @default.
• W3136231489 cites W2770072955 @default.
• W3136231489 cites W2775518969 @default.
• W3136231489 cites W2789315292 @default.
• W3136231489 cites W2793167197 @default.
• W3136231489 cites W2803901052 @default.
• W3136231489 cites W2831487285 @default.
• W3136231489 cites W2886247697 @default.
• W3136231489 cites W2888599070 @default.
• W3136231489 cites W2889317689 @default.
• W3136231489 cites W2891114096 @default.
• W3136231489 cites W2895392798 @default.
• W3136231489 cites W2899240190 @default.
• W3136231489 cites W2901341811 @default.
• W3136231489 cites W2901974641 @default.
• W3136231489 cites W2921962307 @default.
• W3136231489 cites W2949277199 @default.
• W3136231489 cites W2950056455 @default.
• W3136231489 cites W2951820996 @default.
• W3136231489 cites W2994969601 @default.
• W3136231489 cites W2998446840 @default.
• W3136231489 cites W2999042597 @default.
• W3136231489 cites W3003426756 @default.
• W3136231489 cites W3006125663 @default.
• W3136231489 cites W3016806376 @default.
• W3136231489 cites W3018517995 @default.
• W3136231489 doi "https://doi.org/10.1093/rheumatology/keab249" @default.
• W3136231489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33725115" @default.
• W3136231489 hasPublicationYear "2021" @default.
• W3136231489 type Work @default.
• W3136231489 sameAs 3136231489 @default.
• W3136231489 citedByCount "13" @default.
• W3136231489 countsByYear W31362314892022 @default.
• W3136231489 countsByYear W31362314892023 @default.
• W3136231489 crossrefType "journal-article" @default.
• W3136231489 hasAuthorship W3136231489A5000662815 @default.
• W3136231489 hasAuthorship W3136231489A5001586790 @default.
• W3136231489 hasAuthorship W3136231489A5005673493 @default.
• W3136231489 hasAuthorship W3136231489A5010050124 @default.
• W3136231489 hasAuthorship W3136231489A5011037498 @default.
• W3136231489 hasAuthorship W3136231489A5012112773 @default.
• W3136231489 hasAuthorship W3136231489A5015039672 @default.
• W3136231489 hasAuthorship W3136231489A5025478490 @default.
• W3136231489 hasAuthorship W3136231489A5035640410 @default.
• W3136231489 hasAuthorship W3136231489A5037838523 @default.
• W3136231489 hasAuthorship W3136231489A5041302754 @default.
• W3136231489 hasAuthorship W3136231489A5042125003 @default.
• W3136231489 hasAuthorship W3136231489A5042939436 @default.
• W3136231489 hasAuthorship W3136231489A5044024585 @default.
• W3136231489 hasAuthorship W3136231489A5044284945 @default.
• W3136231489 hasAuthorship W3136231489A5045707486 @default.
• W3136231489 hasAuthorship W3136231489A5048569749 @default.
• W3136231489 hasAuthorship W3136231489A5050382913 @default.
• W3136231489 hasAuthorship W3136231489A5052059190 @default.
• W3136231489 hasAuthorship W3136231489A5056239572 @default.
• W3136231489 hasAuthorship W3136231489A5056853165 @default.
• W3136231489 hasAuthorship W3136231489A5058100097 @default.
• W3136231489 hasAuthorship W3136231489A5063103135 @default.
• W3136231489 hasAuthorship W3136231489A5067323699 @default.
• W3136231489 hasAuthorship W3136231489A5069462815 @default.

• next